BioSpace News Archive

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today reported financial results for fourth quarter and full year 2020 and provided a business update.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will host a key opinion leader (KOL) webinar on DM199, the Company’s lead asset for the treatment of Acute Ischemic Stroke (AIS), on Friday, March 19, 2021 at 12:00pm Eastern Time.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2020.

- TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21 - SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumors in Part A; initial clinical response and safety data anticipated in 2H21

AngioDynamics to Report Fiscal 2021 Third Quarter Financial Results on March 30, 2021

Orionis Biosciences, a life sciences company pioneering innovation in genome-scale drug discovery, and The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.

Magenta Therapeutics to Present at the Oppenheimer 31 st Annual Healthcare Conference

Albertsons Companies is proud to announce that more than 1 million doses of COVID-19 vaccine have been administered to Americans nationwide through its trusted pharmacy teams.

Phase 2 data reported at 2021 AD/PD Conference showed gamma frequency neuromodulation was safe and well tolerated Over the 6-month period, patients in the treatment group exhibited a significant 84% slowing of functional decline in ADCS-ADL scores as well as a significant 83% slowing in memory and cognitive decline as measured by MMSE scores compared to placebo/sham

Users of Net Health’s EHR software solution, Net Health® Wound Care (formerly WoundExpert®), can now place in-chart orders for Smith+Nephew’s (NYSE:SNN) RENASYS GO Negative Pressure Wound Therapy (NPWT) solution under a new agreement between the two companies